SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The $ROSIE project centers around a unique, AI-powered memecoin inspired by "Rosie the Robot," a beloved character known for her role as a caring, motherly robot in popular culture. The purpose of $ROSIE is twofold: entertainment through an interactive AI feature and social impact via charitable donations.  Users can interact with an AI version of Rosie on the project’s website, where they can ask questions and engage in conversations. The utility of $ROSIE goes beyond typical memecoins by enabling users to donate tokens, which will be directed towards charitable causes supporting mothers. Through this initiative, the project combines the viral appeal of meme tokens with meaningful contributions to social causes, while leveraging AI technology to create a novel user experience.

Rosie the Robot

ROSIE CRYPTO is gaining attention, particularly regarding its integration with Phantom Wallet. The community highlights the token's 'early moon' potential and strong momentum, suggesting a possible breakout. Bullish sentiment is building, with many emphasizing it as an opportune entry point.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending due to an FDA investigation into allergic reactions linked to specific lots of its and Grifols' immune globulin products, raising concerns about potential voluntary recalls and revenue impact. The community is discussing the extent of the issue, comparing it to a previous recall, and speculating on possible short-selling manipulation. Despite the concerns, some investors express confidence in the company's fundamentals and long-term growth potential, viewing the dip as a buying opportunity.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending due to renewed interest in its low float and potential for a short squeeze, with some traders drawing comparisons to other high-flying stocks. Community chatter highlights the company's potential crypto treasury and anticipation for news catalysts. Some are wary of the stock's history of volatility and advising caution.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community discusses its recent price movements and potential catalysts, including the ongoing government shutdown and anticipation of XRP ETFs.  Community members are debating entry points, long-term potential, and whether XRP can break through resistance levels.  Broader discussions include Ripple's partnerships and the potential impact of regulatory clarity on the crypto's future.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals ($SNDX) is trending due to an upcoming FDA decision on their drug Revuforj for a specific type of leukemia, with the community debating the likelihood of approval and its potential impact. Some traders point to the drug's existing approval for a related condition and analysts' price targets while others cite concerns about side effects and market manipulation. Discussions also mention potential competition and buyout scenarios.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending due to recent listing news and a surge in interest surrounding its AI agent ecosystem. Community members are actively discussing its potential, the utility of its agents, and possible price targets. The broader context includes the growing excitement around AI-related crypto projects and Base network tokens.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

Picard Medical (PMI) is trending due to recent stock volatility, leading the company to release a statement clarifying they are unaware of any undisclosed material changes. The community is actively discussing potential Monday catalysts, dilution concerns, and whether the stock presents a buying opportunity or a trap. Bullish sentiment revolves around the company's exclusive artificial heart technology and potential for a v-shape recovery.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending as its community rallies around the project, anticipating a significant breakout. The community, known as the Wolfpack, expresses strong conviction and emphasizes holding for long-term gains. Discussions highlight the project's potential and a belief that a substantial upward movement is on the horizon.

PAW Chain has launched the world’s first Layer 3-centric blockchain, enhancing scalability and inter-chain operability across networks. The roadmap features a decentralized exchange, merchant services, and a DAO, all optimized for high-volume, low-cost transactions. Leveraging smart contracts and EVM compatibility, PAW Chain is set to transform digital finance by providing secure, efficient solutions, allowing any project to go multi-chain, underscored by a community-driven governance model and rigorous security standards including regular security audits.

$PAW is trending amidst community excitement surrounding its multi-chain ecosystem and ongoing development, including news about new projects launching and validator updates. Community members express bullish sentiment, focusing on the project's potential for growth and interoperability. Discussions also highlight staking and upcoming partnerships.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community speculates on the impact of recent news and exchange listings. Community members are actively discussing price predictions and potential catalysts for growth, drawing comparisons to other meme coins. The listing and broader discussions around meme coins are driving interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings Top Estimates

Kamada (KMDA) delivered earnings and revenue surprises of +44.44% and -0.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates

Coya Therapeutics, Inc. (COYA) delivered earnings and revenue surprises of -63.64% and -96.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2.33% and -84.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Deutsche Bank bearish on European pharma stocks into Q2 amid political headwinds

Investing.com -- Deutsche Bank has made several rating and target price adjustments across the European pharmaceuticals space ahead of second-quarter earnings, flagging continued weakness in the sector and potential opportunities in select names.

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Equity

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Germany-based biotechnology firm BioNTech SE (BNTX) on Thursday said that it intends to acquire its peer CureVac (CVAC) in an all-stock transaction. CVAC stock shot up by about 32% in pre-market trading.Under the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/12/3098162/0/en/BioNTech-Announces-Strategic-Transaction-to-Acquire-CureVac-in-Public-Exchange-Offer.html">deal</a>, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares, resulting in an implied aggregate equity value for CureVac of roughly $1.25 billion.BioNTech also stated that the purchase consideration is subject to a collar mechanism. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.Upon closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.BioNTech will own 100% of CureVac and its subsidiaries, and it will integrate CureVac’s research and manufacturing site in Tübingen.The companies stated that the acquisition will create long-term value for shareholders of both companies and will build on BioNTech’s track record in messenger ribonucleic acid (mRNA) commercialization, including its mRNA-based COVID-19 vaccine developed in collaboration with Pfizer Inc (PFE).CureVac is developing a class of medicines in oncology and infectious diseases based on mRNA. BioNTech said that the transaction will strengthen the research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy candidates.The transaction is expected to close in 2025, subject to the completion of customary closing conditions and receipt of regulatory approvals.On Stocktwits, retail sentiment around CureVac jumped from ‘bearish’ to ‘bullish’ over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_8_42_07_AM_png_e0cc4dfb95.webp" alt="CVAC's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="628" height="67"><figcaption>CVAC's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, who claims to hold CureVac shares, expressed disappointment, opining that they could have gotten a better deal.<stembedurl>https://stocktwits.com/Jbjb90/message/617662210</stembedurl>Meanwhile, retail sentiment around BioNTech rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:629/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_8_44_46_AM_png_29640c1cdc.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="629" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said the deal might lead to a “breakthrough” in cancer treatment.<stembedurl>https://stocktwits.com/quinny2021/message/617661886</stembedurl><a href="https://stocktwits.com/symbol/BNTX">BNTX</a> is trading 1% higher in pre-market.While BNTX shares are down by about 9% this year, <a href="https://stocktwits.com/symbol/CVAC">CVAC shares</a> are up by about 18%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/synopsys-restarts-partial-services-in-china-amid-us-export-curbs/chlXDS8Rb6s">Synopsys Reportedly Restarts Partial Services In China Amid US Export Curbs, But Retail Remains Skeptical</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment

Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares.

CureVac stock soars about 30% after BioNTech agrees to acquire co 

Investing.com -- CureVac NV (NASDAQ:CVAC) stock soared 29.5% on Thursday pre-market trading after German biotech firm BioNTech SE (NASDAQ:BNTX) said it would acquire the company for approximately $1.25 billion.

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

CureVac N.V.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CVAC
CureVac N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CVAC News

CVACCureVac N.V.